Technical Analysis for LXEO - Lexeo Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | N/A | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| NR7 | Range Contraction | 0.00% | |
| Narrow Range Bar | Range Contraction | 0.00% | |
| 20 DMA Resistance | Bearish | -1.20% | |
| Shooting Star Candlestick | Bearish | -1.20% | |
| Lizard Bearish | Bearish Day Trade Setup | -1.20% | |
| Gapped Up | Strength | -1.20% | |
| 20 DMA Resistance | Bearish | 0.00% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
| Pocket Pivot | Bullish Swing Setup | -1.60% |
| Alert | Time |
|---|---|
| Possible NR7 | about 13 hours ago |
| Fell Below 10 DMA | about 15 hours ago |
| 20 DMA Resistance | about 16 hours ago |
| Down 2 % | about 16 hours ago |
| Rose Above 20 DMA | about 17 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 02/28/2024
Lexeo Therapeutics, Inc. Description
Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020 to treat ARVC caused by mutations in the PKP2 gene; LX2021 to treat DSP Cardiomyopathy associated with Cx43 deficiency; and LX2022 to treat HCM associated with mutations in the TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of POE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Disease Rare Diseases Gene Therapy Applied Genetics Cardiomyopathy Lipid Storage Disorders Ataxia Friedreich's Ataxia
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 22.33 |
| 52 Week Low | 9.0 |
| Average Volume | 124,009 |
| 200-Day Moving Average | 0.00 |
| 50-Day Moving Average | 14.10 |
| 20-Day Moving Average | 12.51 |
| 10-Day Moving Average | 12.31 |
| Average True Range | 0.95 |
| RSI (14) | 42.20 |
| ADX | 16.22 |
| +DI | 17.94 |
| -DI | 18.19 |
| Chandelier Exit (Long, 3 ATRs) | 12.94 |
| Chandelier Exit (Short, 3 ATRs) | 14.41 |
| Upper Bollinger Bands | 13.33 |
| Lower Bollinger Band | 11.69 |
| Percent B (%b) | 0.37 |
| BandWidth | 13.16 |
| MACD Line | -0.55 |
| MACD Signal Line | -0.64 |
| MACD Histogram | 0.0908 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 12.99 | ||||
| Resistance 3 (R3) | 13.03 | 12.85 | 12.88 | ||
| Resistance 2 (R2) | 12.85 | 12.67 | 12.83 | 12.84 | |
| Resistance 1 (R1) | 12.57 | 12.56 | 12.48 | 12.53 | 12.80 |
| Pivot Point | 12.39 | 12.39 | 12.34 | 12.37 | 12.39 |
| Support 1 (S1) | 12.11 | 12.21 | 12.02 | 12.07 | 11.80 |
| Support 2 (S2) | 11.93 | 12.10 | 11.91 | 11.76 | |
| Support 3 (S3) | 11.65 | 11.93 | 11.73 | ||
| Support 4 (S4) | 11.61 |
